DNA blood tests could Fine-Tune lymphoma care
NCT ID NCT03758989
First seen Feb 10, 2026 · Last updated May 01, 2026 · Updated 16 times
Summary
This study looks at whether combining PET scans with a blood test that measures tumor DNA can better track how well treatment is working in people with early-stage diffuse large B-cell lymphoma (DLBCL). About 40 adults with untreated limited-stage DLBCL will receive standard chemotherapy (R-CHOP) and have their PET scans and blood DNA levels compared. The goal is to see if these tools can spot treatment failure early and help personalize future therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
Contact
Conditions
Explore the condition pages connected to this study.